Form 4: Edgewise Therapeutics Director Arlene Morris Granted 30,000 Stock Options

Edgewise Therapeutics, Inc. Director Arlene Morris was granted 30,000 stock options with an exercise price of $14.68, vesting on June 16, 2026, or earlier.

Summary

• Arlene Morris, a Director of Edgewise Therapeutics, Inc. (EWTX), was granted 30,000 stock options.
• The options have an exercise price of $14.68 per share.
• The grant date for these options was June 16, 2025.
• The options will become 100% vested on the earlier of June 16, 2026, or the business day prior to the 2026 annual meeting of stockholders.
• The expiration date for these stock options is June 16, 2035.
• Following this transaction, Arlene Morris beneficially owns 30,000 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options aligns the director's interests with shareholders, which is generally viewed favorably. However, it is largely neutral as it represents a routine compensation event.

Positives

• The grant of stock options aligns the interests of Director Arlene Morris with those of the shareholders, as her compensation is tied to the company's stock performance.
• The options have a long expiration date (June 16, 2035), providing a significant window for potential value realization.

Negatives

• The exercise of these options in the future could lead to a minor dilutive effect on existing shares, although this is a standard aspect of equity compensation plans.

Future Outlook

The stock options granted to Director Arlene Morris are set to vest on June 16, 2026, or earlier, contingent on the 2026 annual meeting of stockholders, and will remain exercisable until June 16, 2035.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industry, as well as across publicly traded companies, to incentivize leadership and align their financial interests with long-term shareholder value. This type of equity compensation is a standard component of executive and director remuneration packages.

Comparison to Industry Standards

• Granting stock options as part of director compensation is a widely accepted practice across industries, including the biotechnology sector, to align director incentives with company performance.
• The specific number of options (30,000) and the exercise price ($14.68) are specific to Edgewise Therapeutics and its compensation policies, and without detailed peer compensation data, a direct comparison to specific comparable companies or projects is not feasible based solely on this document.

Related Party Transactions

• The grant of 30,000 stock options to Arlene Morris, a Director of Edgewise Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided to an insider.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from increased alignment of director's interests with company performance.
• Director (Arlene Morris): Receives equity-based compensation, aligning her financial incentives with the company's stock price appreciation.

Next Steps

• The stock options will vest on the earlier of June 16, 2026, or the business day prior to the 2026 annual meeting of stockholders.
• Arlene Morris may choose to exercise these options at any time after vesting and before the expiration date of June 16, 2035.

Key Dates

Keywords

Edgewise Therapeutics, EWTX, Stock Options, Form 4, Insider Transaction, Director Compensation, Equity Grant, Beneficial Ownership